News

Southern Spine Announces John E. Hart as President and Chief Executive Officer

Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced that John E Hart has been named as President and Chief Executive Officer to lead the company.

Hart has more than 35 years of executive leadership experience in the medical device, life science and biologics fields serving in general management, marketing, sales, business development and operational management roles. Most recently, Hart served as a member of the turnaround team at Conmed Corporation, where he led the Cardiology and Critical Care Division to double digit revenue and profit growth. He also led the Healthcare Solutions team which was responsible for corporate, national and government accounts. Prior to that he served as Chief Operating Office for ISTO Technologies, Inc. for 3 years and President and CEO of Vidar Systems Corporation for 5 years. Both companies achieved successful exits.

“John is the right leader for Southern Spine,” said Hugh F. Smisson, III M.D., Southern Spine’s Chairman of the Board. “John’s extensive background in management, sales, marketing and business development should help strengthen our partnerships, develop strategic alliances, expand our sales presence and grow our profitability in the spine and pain markets.”

“I am very excited to be joining the Southern Spine team,” said John Hart. “I believe that Southern Spine’s great products and talented team will be key factors in leading the company’s next chapter for success and growth with the exciting Stabilink® MIS Interlaminar Spinal Fixation System.

John has also held senior executive positions in Fortune 500 companies, including Stryker Orthopaedics (Stryker Corporation) and U.S. Surgical (Covidien – now Medtronic).

John holds a BS degree from The College of New Jersey and an MBA from Southern New Hampshire University. He is a member of the Board of Directors for Virginia Bio.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation